نبذة مختصرة : Prognostic nutritional index (PNI), which is calculated using the albumin level reflectingnutritional status and lymphocyte count reflecting immune status, is useful in showing nutritionaland immunological status related to survival and prognosis in many cancers. In this study, we aimedto evaluate the biomarker potential and effect of PNI in determining the prognosis of metastaticcastration-sensitive prostate cancer (mCSPC). This retrospective observational study included thecomplete data of 108 patients with mCPSC who were treated for at least three months between1 January 2010, and 1 June 2021. The relationships between cancer-specific survival (CSS), overallsurvival (OS), progression-free survival (PFS), and PNI were evaluated. The Kaplan–Meier methodfor OS, PFS, and CSS, as well as univariate and multivariate Cox regression models, were used forthe statistical analyses. The median age of 108 patients included in the study was 68.54 (61.05–74.19)years. A value of 49.75 was determined to be the best cut-off point for the PNI. OS (months) wasfound to be significantly lower in patients with low PNI (median: 34.93, 95% CI: 21.52–48.34) thanin patients with high PNI (median: 65.60, 95% CI: 39.36–91.83) (p = 0.016). Patients with high PNI(median: 48.20, 95% CI: 34.66–61.73) had significantly better CSS (months) than patients with lowPNI (median: 27.86, 95% CI: 24.16–31.57) (p = 0.001). There was no statistically significant differencein PFS between patients with high PNI values (median: 24.60, 95% CI: 10.15–39.05) and patients withlow PNI values (median: 20.03, 95% CI: 11.06–29.03) (p = 0.092). The PNI is a good predictor of OSand CSS in patients with mCSPC. The prediction of PFS, albeit showing a trend towards significance,was not statistically significant, probably due to the small number of cases.
Processing Request
No Comments.